Floatz logo

Dfn-15

Erythrodysesthesia Syndrome

Affiliated Hospital of Qinghai UniversityPhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Erythrodysesthesia Syndrome cohort.

Asset / SponsorPhaseRating
Inno-206
Swiss Cancer Institute
Phase 3BB
Mecobalamin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3B
ADVICOR COMPONENT NIACIN
First People's Hospital of Hangzhou
Phase 2CCC
Tazarotene
Dana-Farber Cancer Institute
Phase 2CCC
INDOMETACINUM
National Taiwan University Hospital
Phase 2CCC

View all 11 →

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →